<生产厂家价格>

正钒酸钠

正钒酸钠用途

Sodium orthovanadate是蛋白酪氨酸磷酸酶,碱性磷酸酶和一些ATP酶的抑制剂,最有可能充当磷酸盐类似物。

正钒酸钠名称

[ CAS 号 ]:
13721-39-6

[ 中文名 ]:
正钒酸钠

[ 英文名 ]:
Sodium orthovanadate

[中文别名 ]:

[英文别名 ]:

Trisodium tetraoxovanadate(3-)
Vanadate(3-), tetraoxo-, sodium (1:3)
sodium tetraoxovanadate(3-)
MFCD00003511
Sodium orthovanadate
EINECS 237-287-9

正钒酸钠生物活性

[ 描述 ]:

Sodium orthovanadate是蛋白酪氨酸磷酸酶,碱性磷酸酶和一些ATP酶的抑制剂,最有可能充当磷酸盐类似物。

[ 相关类别 ]:

信号通路 >> 代谢酶/蛋白酶 >> 磷酸酶

生化试剂

研究领域 >> 癌症

[ 靶点 ]

PPTPase[1].

[体外研究]

在氧化剂存在下,钒离子作为原钒酸钠(钒酸盐：HVO42-或H2VO4-)的水合单体以接近中性pH的微摩尔浓度存在。原钒酸钠(钒酸盐)在中性pH下也开始以大于0.1mM的浓度聚合。通过在数小时的时间后稀释,可以将十钒酸盐的黄橙色溶液转化为单体原钒酸钠(钒酸盐)的无色溶液。通过在pH 10下煮沸来加速该过程,这促进了动力学缓慢的解聚过程[1]。原钒酸钠可改变缺血诱导的丝氨酸83和苏氨酸845的ASK1磷酸化状态。原钒酸钠可以增加PTEN的酪氨酸阳性,并通过在脑缺血期间激活Akt进一步抑制ASK1的活化[2]。

[参考文献]

[1]. Gordon JA, et al. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82.

[2]. Wu DN, et al. Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat hippocampus. Neurosci Lett. 2006 Aug 14;404(1-2):98-102.

[相关活性小分子]

正钒酸钠物理化学性质

[ 熔点 ]:
850-866 °C(lit.)

[ 分子式 ]:
Na₃O₄V

[ 分子量 ]:
183.908

[ 精确质量 ]:
183.892929

[ PSA ]:
86.25000

[ 外观性状 ]:
白色至灰白色粉末

[ 储存条件 ]:
Store at RT

[ 稳定性 ]:
Stable. Incompatible with strong oxidizing agents.

[ 水溶解性 ]:
soluble

正钒酸钠MSDS

详细MSDS(安全技术说明书)

正钒酸钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YW1120000

CHEMICAL NAME :: Vanadic(II) acid, trisodium salt

CAS REGISTRY NUMBER :: 13721-39-6

LAST UPDATED :: 199706

DATA ITEMS CITED :: 39

MOLECULAR FORMULA :: O4-V.3Na

MOLECULAR WEIGHT :: 183.91

WISWESSER LINE NOTATION :: NA3 VA-O4

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 330 mg/kg

TOXIC EFFECTS :: Gastrointestinal - hypermotility, diarrhea Blood - hemorrhage

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 36300 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 9280 ug/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea Blood - hemorrhage

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 1 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5054 mg/kg/10W-I

TOXIC EFFECTS :: Behavioral - excitement Gastrointestinal - ulceration or bleeding from small intestine Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 33750 ug/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 300 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: Micronucleus test

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Sex chromosome loss and nondisjunction

MUTATION DATA

TYPE OF TEST :: Mutation test systems - not otherwise specified

TEST SYSTEM :: Mammal - species unspecified Kidney

REFERENCE :: JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 79,573,1978 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992

正钒酸钠安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302 + H312 + H332

[ 警示性声明 ]:
P280

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xn:Harmful;

[ 风险声明 (欧洲) ]:
R20/21/22

[ 安全声明 (欧洲) ]:
S22-S36

[ 危险品运输编码 ]:
UN3285

[ WGK德国 ]:
3

[ RTECS号 ]:
YW1120000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1

正钒酸钠文献

A survey of the interactome of Kaposi's sarcoma-associated herpesvirus ORF45 revealed its binding to viral ORF33 and cellular USP7, resulting in stabilization of ORF33 that is required for production of progeny viruses.

J. Virol. 89(9) , 4918-31, (2015)

The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus-specific immediate-early tegument protein. Our previous studies have revealed its crucial roles in both early ...

Progressive accumulation of activated ERK2 within highly stable ORF45-containing nuclear complexes promotes lytic gammaherpesvirus infection.

PLoS Pathog. 10(4) , e1004066, (2014)

De novo infection with the gammaherpesvirus Rhesus monkey rhadinovirus (RRV), a close homolog of the human oncogenic pathogen, Kaposi's sarcoma-associated herpesvirus (KSHV), led to persistent activat...

Disturbed Hsp70 and Hsp27 expression and thiol redox status in porcine kidney PK15 cells provoked by individual and combined ochratoxin A and citrinin treatments.

Food Chem. Toxicol. 71 , 97-105, (2014)

The aim of this study was to explore the oxidative properties of ochratoxin A (OTA) and citrinin (CTN) as a possible underlying mechanism of their individual and/or combined cytotoxicity. Metabolic ac...

更多文献